Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Eli Lilly 22.974, Novo Nordisk 12.087.
Eli Lilly vs Novo Nordisk Net Worth and Market Cap
Eli Lilly (LLY) and Novo Nordisk (NVO) are peers in GLP-1. Eli Lilly reported revenue of $23.0B as of Q2 2026, compared with $12.1B for Novo Nordisk. Eli Lilly leads on revenue.
Eli Lilly's gross margin is 85.8% versus 78.2% for Novo Nordisk. Eli Lilly's net margin is 30.9% versus 26.7% for Novo Nordisk.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Eli Lilly +47.7%, Novo Nordisk +2.1%.
- Eli Lilly keeps more of its revenue as operating profit: a 54.2% operating margin, against 34.5% at Novo Nordisk.
- Eli Lilly's KPIs on Sterling include Cardiometabolic Manufacturing Capex Announcements by Site (Cumulative) and Foundayo Quarterly Revenue.
- Novo Nordisk's KPIs on Sterling include Next-Generation Obesity: CagriSema + Amycretin Readouts and 2030 Ambitions (Capital Markets Day, 21 Sep 2026).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Novo Nordisk.| Metric | Eli Lilly | Novo Nordisk |
|---|---|---|
| Market Cap | - | - |
| Revenue | $22.97B | $12.09B |
| Cost of Revenue | $3.27B | $2.63B |
| Gross Profit | $19.71B | $9.45B |
| Operating Income | $12.46B | $4.17B |
| Net Income | $7.09B | $3.23B |
| R&D Expense | $3.82B | $2.74B |
| Earnings Per Share | $7.94 | $0.73 |
| Gross Margin | 85.8% | 78.2% |
| Operating Margin | 54.2% | 34.5% |
| Net Profit Margin | 30.9% | 26.7% |
| Free Cash Flow | $7.76B | $6.53B |
| Cumulative Free Cash Flow | $109.66B | $107.39B |
| Operating Cash Flow | $10.69B | $8.50B |
| Cash & Equivalents | $8.89B | $6.85B |